ACS Omega
July 10, 2025
Taynah Pereira Galdino, Lucas C Oliveira, Mateus A Luz et al.
5 citations
A validated HPLC-DAD method quantifies psilocybin and psilocin in psychedelic mushroom extracts for medicinal use. Following Brazilian ANVISA guidelines, the method achieved detection limits of 1.58 mg/L for psilocybin and 1.70 mg/L for psilocin, with quantification limits of 4.78 and 5.17 mg/L, respectively. Recovery intervals ranged from 80–120% for psilocybin and 98–116% for psilocin. The mushroom samples contained 2.57% psilocybin and 0.16% psilocin. Accurate measurement of these compounds supports their reliable use in therapeutic contexts, emphasizing the need for precise quantification in developing safe medical treatments.
Pharmaceuticals
July 1, 2025
Mateus Araújo Da Luz, H. Guedes, Antônio B. M. Bisneto et al.
5 citations
A review of 74 articles on Psilocybe mushrooms found that 66 reported psilocybin or psilocin, confirming psychoactivity, while 4 demonstrated antimicrobial and antioxidant activities of whole extracts. Across the genus, 37 chemical compounds were identified, 23 of which are alkaloids. Only alkaloids, terpenoids, and phenolic compounds were found, totaling just 36 compounds over 67 years of study. Most research focused on tryptamine alkaloids responsible for psychoactivity, with no studies examining isolated compounds against specific pathological factors except for whole-extract larvicidal, antimicrobial, and antioxidant potential. The authors suggest that future work should isolate new compounds and evaluate alternative biological activities.
ACS Omega
September 16, 2025
Lucas Cordeiro de Oliveira, Taynah Pereira Galdino, Marcelo Da Silva Pedro et al.
1 citation
N,N-Dimethyltryptamine (DMT), a plant-derived alkaloid, shows therapeutic potential for mental health disorders. An efficient method was established to extract, isolate, and characterize DMT from Mimosa tenuiflora, comparing root bark and stem bark. The stem bark method (sample 2C) yielded 3.45% pure DMT (0.172 g from 5.0003 g powder) and a robust phytochemical profile with alkaloids, tannins, and flavonoids. Characterization confirmed DMT identity via FTIR, HPLC-DAD (retention time 11.81 min), and GC-MS (retention time 16.4 min, 88% spectral similarity). Thermogravimetric analysis showed thermal stability up to 135 °C. Cellular viability exceeded 85% at therapeutic concentrations, with reduction only at 100 μg/mL (53 ± 21%), possibly due to overexposure. Sample 2C is a promising candidate for standardized DMT pharmaceutical formulations.
ACS Omega
September 15, 2025
Taynah Pereira Galdino, Antônio Braz de Medeiros Bisneto, Marcelo Da Silva Pedro et al.
1 citation
An active pharmaceutical ingredient (API) extracted from Psilocybe mushrooms yielded approximately 20% of target compounds, with psilocybin and psilocin contents of 3.26% and 0.34%, respectively. The API showed high purity, stability, solubility in polar solvents, low toxicity, and compliance with limits for heavy metals and microbes. It is compatible with polymeric matrices for controlled release. The work demonstrates the feasibility of a standardized psilocybin-based API for treating mental disorders.
Journal of the Brazilian Chemical Society
January 1, 2026
Mateus Araújo Da Luz, Taynah Pereira Galdino, Lucas Matheus da S. Oliveira et al.
Optimizing the extraction of psilocybin from Psilocybe cubensis mushrooms using an acidified ethanol solvent at pH 2 and 25 °C, without added water, yields up to 50.03 mg of psilocybin per gram of extract (about 1% psilocybin). This exceeds yields reported in similar studies. Analysis by liquid chromatography-mass spectrometry identified six compounds: the known indole alkaloids psilocybin and psilocin, plus four compounds not previously reported in the Psilocybe genus—sn-glycero-3-phosphocholine, norvaline, tetronomycin, and N-(tetradecanoyl)-sphinganine.